News & Updates
Showing Pharmacy articles
Showing

Panitumumab plus trifluridine-tipiracil confers survival advantage in RAS wild-type MCRC
In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.

Herbal combination works in treatment of active ulcerative colitis
The herbal combination of curcumin plus QingDai (CurQD) appears beneficial to patients with active ulcerative colitis (UC), with a recent study showing that the combination induced clinical and biomarker remission.

Conventional vs shorter ocrelizumab infusions: which way to go?
In the ENSEMBLE PLUS study, there appears to be no difference in terms of the frequency and severity of infusion-related reactions (IRRs) between the conventional and shorter infusions of ocrelizumab for the treatment of early relapsing-remitting multiple sclerosis (RRMS). However, patients gravitated towards the shorter regimen more than the conventional method.






